Evaluation of Benztropine for Cocaine Craving - 2

NCT ID: NCT00000333

Last Updated: 2017-02-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2001-05-31

Study Completion Date

2003-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Benztropine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Please contact site for information.
Minimum Eligible Age

22 Years

Maximum Eligible Age

48 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Washington D.C. Veterans Affairs Medical Center

FED

Sponsor Role collaborator

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven Deutsch, M.D.

Role: PRINCIPAL_INVESTIGATOR

Washington D.C. Veterans Affairs Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Washington DC VA

Washington D.C., District of Columbia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Y01-3-0009-2

Identifier Type: -

Identifier Source: secondary_id

NIDA-3-0009-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cocaine Use Disorder and Cortical Dopamine
NCT03349606 COMPLETED EARLY_PHASE1
Quetiapine for Cocaine Use and Cravings
NCT00232336 COMPLETED PHASE4
Prazosin for ETOH or Cocaine Craving
NCT00240227 TERMINATED NA
[C-11]NPA PET-amphetamine in Cocaine Use Disorders
NCT05011760 RECRUITING EARLY_PHASE1